Eyeon Therapeutics Out-Licenses Proprietary OTC Dry Eye Product

BETHLEHEM, Pa., July 28, 2016 /PRNewswire/ -- Eyeon Therapeutics has licensed the North American rights to its patents and pending intellectual property for over-the-counter ophthalmic products to an undisclosed licensee. The agreement was executed in May and is the latest step in commercializing this polymer technology developed at Particles Sciences, a Lubrizol Advanced Materials, Inc. LifeSciences Group company and a leading drug delivery CDMO. Eyeon also filed a follow-on PCT application this month to enhance its already strong and broad global intellectual property position.

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "We are grateful to Particle Sciences for their support in helping us develop and advance this important new technology designed to provide a better treatment opportunity for dry eye patients, and we are delighted to have found an excellent commercial organization to bring this technology to patients with dry eye disease in North America.  In the coming months we will continue to develop relationships with commercial organizations in vision care and eye pharma regarding remaining rights to the technology." 

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. Visit www.particlesciences.com, email [email protected], or contact us at (610) 861- 4701 for information.

Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at [email protected]

Contact:
Maureen Grieco
610-861-4701
[email protected]

SOURCE Particle Sciences

Related Links

http://www.particlesciences.com